Cardiovascular Toxicity of Novel HER2-Targeted Agents and Multikinase Inhibitors in Oncology: From Mechanisms to Real-World Clinical Evidence. - Abu Suleiman A; Quagliariello V; Spadafora L; Russo F; Maurea N (Pharmaceuticals (Basel, Switzerland), 2026)